查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球系統性紅斑狼瘡市場
市場調查報告書
商品編碼
1279681

2023-2030 年全球系統性紅斑狼瘡市場

Global Systemic Lupus Erythematosus Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球系統性紅斑狼瘡市場預計將實現利潤豐厚的增長，到 2022 年將達到 18.932 億美元，到 2030 年將達到 32.957 億美元。 系統性紅斑狼瘡市場預計在預測期內（2023-2030 年）的複合年增長率為 7.3%。

系統性紅斑狼瘡 (SLE) 是一種慢性自身免疫性疾病，免疫系統錯誤地攻擊健康組織，對皮膚、關節、腎臟、心臟、肺、大腦等造成傷害。你可能會。 SLE 在女性中更為常見，通常發生在 25 至 45 歲之間。

它會導致慢性炎症和各種症狀，並可能降低人的生活質量。 全球系統性紅斑狼瘡市場預計在未來幾年將顯著增長，原因是對該疾病的了解增加、診斷率提高以及新療法的發現。

市場動態

政府舉措的增加有望推動全球系統性紅斑狼瘡市場的增長

世界各國政府正在努力改善 SLE 治療的可及性和治療方法，增加研發資金，並促進監管以改善患者預後。是。

例如，根據美國疾病控制與預防中心 (CDC) 2022 報告，CDC-RFA-DP20-2008 是一個為期五年的合作物。 該合作協議的基本目標是支持國家組織並與國家組織建立夥伴關係，以提高國家對狼瘡的認識和能力。

該協議旨在增加能夠識別狼瘡體徵並在檢測到時做出適當反應的醫護人員的數量。 此外，該協議旨在增加狼瘡患者對自我管理工具和服務的參與，從而使患者的自我管理行為發生積極變化。 因此，上述因素預計將在預測期內推動全球系統性紅斑狼瘡市場的增長。

全球系統性紅斑狼瘡市場可能面臨治療副作用的限制

許多現有的 SLE 藥物具有潛在的嚴重副作用，可能會阻止患者使用它們。 患者不願採用具有顯著副作用的療法可能是一個重要的市場限制。

潑尼松是皮質類固醇的一個例子，它可以幫助減輕炎症和緩解關節疼痛和皮疹等症狀，但它也可能有嚴重的副作用，例如體重增加、高血壓和骨質疏鬆症。

COVID-19 影響分析

隨著 COVID-19 的流行，系統性紅斑狼瘡 (SLE) 對全球市場產生了重大影響。 限制患者獲得醫療保健是大流行的重大影響之一。 許多系統性紅斑狼瘡患者的免疫系統較弱，更有可能發展為嚴重的 COVID-19，導致醫療關注減少以及識別和治療延誤。

這會對患者的治療結果產生負面影響。 COVID-19 疫情阻礙了 SLE 藥物進入市場，導致患者和醫療保健系統出現短缺和價格上漲。

俄烏衝突分析

俄羅斯和烏克蘭之間的衝突可能會對全球系統性紅斑狼瘡 (SLE) 市場產生意想不到的後果，尤其是 SLE 藥物的供應鏈。 烏克蘭正在成為一個重要的製藥商，並向其他國家出口藥品。 如果生產設施或運輸路線因戰爭而被毀壞或關閉，可能會影響 SLE 藥物的供應鏈。

此外，由於衝突，當地醫療保健基礎設施和可及性可能會下降，導致烏克蘭及周邊地區的系統性紅斑狼瘡 (SLE) 患者等待診斷和治療的時間很長。 然而，系統性紅斑狼瘡的全球市場是多樣化的，藥物供應並不嚴重依賴於任何特定的地區或國家。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 按藥物類別分類的片段
  • 按投放方式分類的摘要
  • 按銷售渠道
  • 區域摘要

第四章市場動態

  • 影響因素
    • 主持人
      • 預計政府舉措的增加將推動全球系統性紅斑狼瘡市場
    • 約束因素
      • 全球系統性紅斑狼瘡市場可能面臨治療特異性副作用的限制
    • 機會
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法律法規分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格和動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章藥物類別

  • 抗瘧藥
  • 非甾體抗炎藥
  • 細胞毒性/免疫抑製劑
  • 生物製品
  • 其他

第八章交付模式

  • 靜脈給藥
  • 皮下給藥
  • 口語
  • 局部管理

第 9 章分銷渠道

  • 零售藥房
  • 醫院藥房
  • 在線藥店

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 競爭場景
  • 市場定位/份額分析
  • 併購分析

第12章公司簡介

  • Anthera 製藥公司
    • 公司簡介
    • 產品組合和說明
    • 財務摘要
    • 主要發展狀況
  • Eli Lilly
  • GlaxoSmithKline Plc
  • F. Hoffmann-La Roche Ltd
  • Pfizer Limited
  • Sanofi
  • Lycera Corporation
  • Bristol-Myers Squibb
  • ImmuPharma Plc
  • Merck KGaA

第13章 附錄

簡介目錄
Product Code: PH51

Market Overview

The global systemic lupus erythematosus market reached US$ 1,893.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 3,295.7 million by 2030. The systemic lupus erythematosus market is expected to exhibit a CAGR of 7.3% during the forecast period (2023-2030).

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can harm the skin, joints, kidneys, heart, lungs, and brain by causing the immune system to wrongly target healthy tissues. SLE is more frequent in women and usually occurs between the ages of 25 and 45.

Chronic inflammation and a variety of symptoms can be caused by the condition, lowering a person's quality of life. The global market for systemic lupus erythematosus is predicted to rise significantly in the next years due to increasing knowledge of the disorder, higher rates of diagnosis, and the discovery of novel therapies.

Market Dynamics

The Rising Number of Government Initiatives is Expected to Drive the Global Systemic Lupus Erythematosus Market Growth.

Governments throughout the world are working to enhance access to SLE treatments and therapies, increase monetary support for R&D, and promote regulations that improve outcomes for patients.

For instance, according to the Centers for Disease Control and Prevention (CDC) 2022 report, the CDC-RFA-DP20-2008 is a closed Notice of Funding Opportunity (NOFO) with a 5-year collaboration agreement. The fundamental goal of this cooperation agreement is to support national organizations in undertaking national initiatives to improve lupus awareness and abilities, as well as to build collaborations.

The goal of this agreement is to increase the number of healthcare practitioners who can recognize lupus signs and take appropriate action if it is detected. Furthermore, the agreement intends to increase lupus patients' participation in self-management tools and services, resulting in a favorable shift in their self-management behaviors. Therefore, the above-mentioned factors, are expected to drive growth of the global systemic lupus erythematosus market over the forecast period.

The Global Systemic Lupus Erythematosus Market May Face Constraints Due to Adverse Effects of Treatment.

Many of the existing SLE therapies have potentially serious side effects, which may prevent patients from using them. Patients may be reluctant to adopt therapies that have considerable adverse effects, which can be a big market restriction.

Prednisone is an example of a corticosteroid that can help reduce inflammation and relieve symptoms like joint pain and skin rashes, but it can also have serious adverse effects including weight gain, high blood pressure, and osteoporosis.

COVID-19 Impact Analysis

In the wake of the COVID-19 epidemic, Systemic Lupus Erythematosus (SLE) has had a substantial influence on the global market. Restricted patient access to medical care has been one of the pandemic's significant effects. Delays in identification and treatment occur as a result of fewer individuals seeking medical attention due to the fact that many SLE patients have compromised immune systems and are more likely to develop severe COVID-19.

This can have a detrimental effect on patient outcomes. The COVID-19 pandemic has also hampered the flow of SLE medications into the market, resulting in shortages and raising prices for patients and healthcare systems.

Russia Ukraine Conflict Analysis

The crisis between Russia and Ukraine may have unintended consequences for the worldwide market for systemic lupus erythematosus (SLE), especially for the SLE drug supply chain. Ukraine is becoming a significant pharmaceutical manufacturer, exporting medicines to other nations. The supply chain for SLE drugs may be affected if production facilities or shipping routes are destroyed or shut down as a result of the war.

In addition, the conflict may result in a decline in the region's healthcare infrastructure and accessibility, which would cause SLE patients in Ukraine and the surrounding territories to wait longer for diagnosis and treatments. The worldwide market for SLE is diversified, nevertheless, and does not rely largely on any one area or nation for the provision of medicines.

Segment Analysis

The global systemic lupus erythematosus market is segmented based on drug class, mode of delivery, distribution channel, and region.

The Hospital Pharmacies Segment is Expected to Dominate the Global Systemic Lupus Erythematosus Market.

The systemic lupus erythematosus (SLE) medication distribution is anticipated to be dominated by hospital pharmacies on a worldwide scale accounting market share of 42.4%. Hospital pharmacies may supply patients with the essential drugs and other therapies and are the main point of care for SLE patients, especially those with severe or complex forms of the condition. Personalised drug dosage and monitoring, as well as access to specialised therapies like intravenous infusions or diagnostic testing, are advantages that hospital pharmacists offer.

Additionally, they already have contacts with healthcare professionals, which makes it simpler to prescribe and monitor drugs as well as to communicate and coordinate treatment. Therefore, owing to the above factors, the hospital pharmacies segment is likely to play major role in accelarating the global systemic lupus erythematosus market growth.

Geographical Analysis

North America Region Holds The Largest Market Share of the Global Systemic Lupus Erythematosus Market.

The global systemic lupus erythematosus market is dominated by North America and holds 1/3rd market share, due to a number of factors, first off, there is more knowledge regarding SLE in this area, which has improved knowledge of the condition and available treatments. Second, compared to other locations, North America has a more established healthcare system, which gives SLE sufferers greater access to medical care and specialised therapies.

In addition, there have been more foundations and independent venture firms funding North American biopharmaceutical producers, which has aided in the creation of novel SLE medications and treatments. For instance, in March 2023, AbbVie revealed the findings of a Phase II research in patients with moderately to highly active systemic lupus erythematosus (SLE) with upadacitinib (RINVOQ, 30 mg) administered alone or in combination treatment (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg) once daily.

Competitive Landscape

The major global players in the market include: Anthera Pharmaceuticals, Eli Lilly, GlaxoSmithKline, F. Hoffmann-La Roche, Pfizer Limited, Sanofi, Lycera Corporation, Bristol-Myers Squibb, ImmuPharma Plc, and Merck KGaA.

Why Purchase the Report?

  • To visualize the global systemic lupus erythematosus- market segmentation based on drug class, mode of delivery, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global systemic lupus erythematosus market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global systemic lupus erythematosus market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Mode of Delivery
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising number of government initiatives is expected to drive the global systemic lupus erythematosus market.
    • 4.1.2. Restraints
      • 4.1.2.1. The global systemic lupus erythematosus market may face constraints due to adverse effects of treatment.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Antimalarial Drugs
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Non-Steroidal Anti-Inflammatory Drugs
  • 7.4. Cytotoxic And Immunosuppressive Drugs
  • 7.5. Biologics
  • 7.6. Others

8. By Mode of Delivery

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 8.1.2. Market Attractiveness Index, By Mode of Delivery
  • 8.2. Intravenous
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Subcutaneous
  • 8.4. Oral
  • 8.5. Topical

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Retail Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Hospital Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Anthera Pharmaceuticals Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Eli Lilly
  • 12.3. GlaxoSmithKline Plc
  • 12.4. F. Hoffmann-La Roche Ltd
  • 12.5. Pfizer Limited
  • 12.6. Sanofi
  • 12.7. Lycera Corporation
  • 12.8. Bristol-Myers Squibb
  • 12.9. ImmuPharma Plc
  • 12.10. Merck KGaA

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us